Industry News
SA researchers to have better access to equipment, expertise
A new South Australian initiative aims to give scientists in that state easier access to expensive research equipment and expertise. [ + ]
Benitec appoints RNAi specialist to head US advisory board
Brisbane gene silencing company Benitec (ASX:BLT) has appointed a specialist in DNA-directed RNA interference to chair its scientific advisory board in the United States. [ + ]
Jacques Miller AC wins Australia's top science prize
Carrying on a strong tradition of world class immunology research in Australia, the A$300,000 Prime Minister's Prize for Science has been awarded to Emeritus Professor Jacques Miller AC of the Walter and Eliza Hall Institute of Medical Research in Melbourne.
[ + ]TGR boss joins Novogen board
Bioactive compound development company Novogen (ASX:NRT) has appointed the chief of biotech TGR BioSsciences to its board of directors. [ + ]
Gribbles enters biotech with genomics coup
Pathology giant Gribbles (ASX:GGL) has announced a new subsidiary dedicated to biotechnology, with its first project being the development of a pre-natal screening test to detect genetic and chromosomal abnormalities. [ + ]
Vic govt tenders for review of biotech plan
The Victorian state government's Department of Innovation, Industry and Regional Development (DIIRD) has put up for tender the review of its Biotechnology Strategic Development Plan. [ + ]
Broaden your audience, analyst tells biotechs
Biotechnology companies need to widen the audiences they pitch their messages to, industry analyst David Blake, of BioShares, told attendees at a BioMelbourne Network breakfast meeting today. [ + ]
Eiffel nets $2.2m Start grant
Melbourne drug re-engineering company Eiffel Technologies Ltd (ASX:EIF) has received a pleasant surprise from the Federal Government: a $2.2 million R&D Start grant. [ + ]
Imugene toasts future after formative year
Despite a decrease in revenues and an increase in net loss to AUD$1.3 million, veterinary biotechnology company Imugene (ASX:IMU) has come a long way in its first year as a biotechnology company, according to chairman Graham Dowland, who said it was a "tremendous formative year." [ + ]
Brutal honesty marks Iatia's response to a tough 12 months
Microscopy company Iatia (ASX:IAT) released its annual results last Friday with a brutally honest assessment of their performance over the 2002-2003 year. [ + ]
Peplin spruiks promising new compound
Brisbane's Peplin Biotech Ltd (ASX:PEP) has had a good week, reporting a promising new indication for its lead anti-cancer compound PEP005, and promising activity from a new compound of undisclosed provenance. [ + ]
BresaGen results sweetened by new ADR status
Adelaide-based biotechnology company BresaGen Ltd (ASX:BGN) has confirmed a consolidated loss for 2002-03 AUD$13.95 million, which it flagged last month, up from $11.86 million in 2002. [ + ]
New firm spruiks S Korea as manufacturing hub
Founded as a joint venture between Californian AIDS vaccine company VaxGen and South Korean investors, manufacturing company Celltrion is being developed to provide large-scale mammalian cell culture manufacturing for the biopharmaceutical industry. [ + ]
Monash researchers claim key MS find
Monash University researchers have solved the crystal structure of the protein suspected to be the focus of the autoimmune attack that destroys the fatty insulating sheath around neurons in the brain in multiple sclerosis (MS). [ + ]
Major new alliance for oil and gas research
Three of Western Australia's major research institutions have formed a united energy research partnership intended to benefit the operations of the global oil and gas industry with leading-edge practical research.
[ + ]
